• FryAI
  • Posts
  • Chat(GPT) with your apps

Chat(GPT) with your apps

In partnership with

FryAI

If you’re new here, welcome to the crispiest AI takes in the world! If you’re an “OG,” you’ve already hit the Mystery Link, tinkered with a cutting-edge AI tool, and enlightened your group chat with an AI story they’d never have heard without you! 😜

(The mystery link can lead to ANYTHING AI-related: tools, memes, articles, videos, and more…)

Learn AI in 5 minutes a day

This is the easiest way for a busy person wanting to learn AI in as little time as possible:

  1. Sign up for The Rundown AI newsletter

  2. They send you 5-minute email updates on the latest AI news and how to use it

  3. You learn how to become 2x more productive by leveraging AI

Today’s Menu

Appetizer: ChatGPT now lets you chat with apps 💬

Entrée: OpenAI signs multi-year deal with AMD ⚡️

Dessert: AI discovers new antibiotic for gut health 🦠

🔨 AI TOOLS OF THE DAY

✝️ Manna: Duolingo for Bible study. → Check it out

💪 Alter: Turn meetings into clear action. → Check it out

CHATGPT NOW LETS YOU CHAT WITH APPS 💬

What’s up? OpenAI just announced new integrations with popular apps, which can be used directly inside ChatGPT.

How does this work? These apps fit naturally into conversation. ChatGPT can suggest them when relevant or you can call them by name, like saying “Spotify, make a playlist for my party.” The apps respond in plain language and include interactive elements, such as maps, playlists, and design tools, that work right in the chat. Early launches include Booking.com, Canva, Coursera, Figma, Expedia, Spotify, and Zillow, while more are on the way. Developers can also create and test their own apps using the open-source SDK built on the Model Context Protocol (MCP).

Why is this important? This update turns ChatGPT into a true all-in-one platform. Users can learn, create, and get things done without ever leaving the chat, while developers gain access to over 800 million potential users—making AI more useful, personal, and integrated than ever before.

OPENAI SIGNS MULTI-YEAR DEAL WITH AMD ⚡️

What’s new? OpenAI has signed a multi-year deal with AMD to deploy 6 gigawatts of AMD Instinct GPUs, beginning with a 1-gigawatt rollout of MI450 chips in the second half of 2026.

Want the details? Under the agreement, OpenAI will use AMD’s next-generation Instinct GPUs to power its expanding AI infrastructure. The partnership extends across multiple generations of hardware, starting with the MI450 series and building on earlier collaborations involving AMD’s MI300X and MI350X chips. AMD has also issued OpenAI a warrant for up to 160 million shares, vesting as deployment and performance milestones are achieved.

Why is this significant? This deal marks one of the largest AI hardware agreements to date, signaling AMD’s growing challenge to Nvidia’s dominance. For OpenAI, it means faster, more cost-efficient compute power to train and run advanced models—fueling progress toward more capable and accessible AI tools that could shape the next era of technology.

Founders need better information

Get a single daily brief that filters the noise and delivers the signals founders actually use.

All the best stories — curated by a founder who reads everything so you don't have to.

And it’s totally free. We pay to subscribe, you get the good stuff.

AI DISCOVERS NEW ANTIBIOTIC FOR GUT HEALTH 🦠

Image: Alex Shipps/MIT CSAIL, using assets from the researchers and Pexels

What’s new? Researchers at MIT and McMaster University used AI to discover a new antibiotic compound, enterololin, that targets harmful bacteria linked to Crohn’s disease without disrupting the rest of the gut microbiome.

Want the details? Enterololin works by zeroing in on Escherichia coli, a bacterium that worsens Crohn’s flare-ups, while leaving beneficial gut bacteria untouched. To uncover how it works, scientists used a generative AI model called DiffDock, which predicts how drug molecules bind to bacterial proteins. The AI quickly identified enterololin’s target—an essential protein complex called LolCDE—allowing researchers to confirm its action in just months rather than years through follow-up lab experiments.

Why does this matter? This discovery marks a major step toward precision antibiotics—treatments that fight disease without harming healthy microbes. By combining AI and biology, scientists may accelerate drug discovery and reduce the global threat of antibiotic resistance.

HAS AI REACHED SINGULARITY? CHECK OUT THE FRY METER BELOW:

What do ya think of this latest newsletter?

Login or Subscribe to participate in polls.

Your feedback on these daily polls helps us keep the newsletter fresh—so keep it coming!